Compare Novartis with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs SUN PHARMA - Comparison Results

NOVARTIS     Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS SUN PHARMA NOVARTIS/
SUN PHARMA
 
P/E (TTM) x 515.4 22.1 2,328.1% View Chart
P/BV x 28.9 2.6 1,114.1% View Chart
Dividend Yield % 1.5 0.6 248.1%  

Financials

 NOVARTIS   SUN PHARMA
EQUITY SHARE DATA
    NOVARTIS
Mar-19
SUN PHARMA
Mar-19
NOVARTIS/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs980679 144.4%   
Low Rs600375 159.9%   
Sales per share (Unadj.) Rs198.7121.1 164.0%  
Earnings per share (Unadj.) Rs21.013.4 156.8%  
Cash flow per share (Unadj.) Rs22.320.7 107.6%  
Dividends per share (Unadj.) Rs10.002.75 363.6%  
Dividend yield (eoy) %1.30.5 242.6%  
Book value per share (Unadj.) Rs307.5172.6 178.2%  
Shares outstanding (eoy) m24.692,399.26 1.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.04.4 91.4%   
Avg P/E ratio x37.739.4 95.6%  
P/CF ratio (eoy) x35.525.5 139.3%  
Price / Book Value ratio x2.63.1 84.1%  
Dividend payout %47.720.6 232.0%   
Avg Mkt Cap Rs m19,5081,264,650 1.5%   
No. of employees `0000.617.5 3.3%   
Total wages/salary Rs m1,17159,671 2.0%   
Avg. sales/employee Rs Th8,445.416,608.1 50.9%   
Avg. wages/employee Rs Th2,015.73,409.6 59.1%   
Avg. net profit/employee Rs Th891.01,833.8 48.6%   
INCOME DATA
Net Sales Rs m4,907290,659 1.7%  
Other income Rs m78310,255 7.6%   
Total revenues Rs m5,689300,914 1.9%   
Gross profit Rs m12363,076 0.2%  
Depreciation Rs m3217,533 0.2%   
Interest Rs m165,553 0.3%   
Profit before tax Rs m85850,246 1.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-12,144 0.0%   
Tax Rs m3406,009 5.7%   
Profit after tax Rs m51832,093 1.6%  
Gross profit margin %2.521.7 11.5%  
Effective tax rate %39.612.0 331.5%   
Net profit margin %10.611.0 95.6%  
BALANCE SHEET DATA
Current assets Rs m8,055310,692 2.6%   
Current liabilities Rs m1,850173,396 1.1%   
Net working cap to sales %126.447.2 267.7%  
Current ratio x4.41.8 243.0%  
Inventory Days Days4599 45.5%  
Debtors Days Days34112 30.4%  
Net fixed assets Rs m150232,477 0.1%   
Share capital Rs m1232,399 5.1%   
"Free" reserves Rs m7,469411,691 1.8%   
Net worth Rs m7,592414,091 1.8%   
Long term debt Rs m015,226 0.0%   
Total assets Rs m9,824646,938 1.5%  
Interest coverage x54.910.0 546.7%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.50.4 111.2%   
Return on assets %5.45.8 93.3%  
Return on equity %6.87.8 88.0%  
Return on capital %11.510.2 113.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m5866,025 0.1%   
Fx outflow Rs m1,32638,610 3.4%   
Net fx Rs m-1,26927,415 -4.6%   
CASH FLOW
From Operations Rs m-1,94321,965 -8.8%  
From Investments Rs m2,742-6,813 -40.3%  
From Financial Activity Rs m-298-27,305 1.1%  
Net Cashflow Rs m501-8,442 -5.9%  

Share Holding

Indian Promoters % 0.0 63.7 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 5.1 39.0%  
FIIs % 1.6 23.0 7.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 8.3 259.0%  
Shareholders   41,647 133,026 31.3%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   JUBILANT LIFE SCIENCES  PANACEA BIOTECH  WOCKHARDT  ABBOTT INDIA  FRESENIUS KABI ONCO.  

Compare NOVARTIS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 208 Points Lower; Oil & Gas and Metal Stocks Witness Selling(Closing)

India share markets continued to witness selling pressure during closing hours and ended their day on a negative note.

Related Views on News

SUN PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 35.3% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, SUN PHARMA has posted a net profit of Rs 15 bn (up 35.3% YoY). Sales on the other hand came in at Rs 84 bn (up 15.9% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

SUN PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Aug 6, 2019 | Updated on Aug 6, 2019

Here's an analysis of the annual report of SUN PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 53.4% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, SUN PHARMA has posted a net profit of Rs 7 bn (down 53.4% YoY). Sales on the other hand came in at Rs 72 bn (up 2.7% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

More Views on News

Most Popular

My Latest Stock Recommendation(Fast Profits Daily)

Jan 10, 2020

The story behind my latest stock recommendation and an important announcement.

Bet on These Smallcap Stocks for Success in 2020(Profit Hunter)

Jan 14, 2020

The smallcap rebound finally seems to here... Make sure you aren't too late to make the most of the biggest wealth making opportunity in a decade.

Your Safe Income Options for 2020(Fast Profits Daily)

Jan 9, 2020

What are you safest investing options in 2020 when interest rates fall.

Guess Which Stocks Are Rising at Double the Speed of Sensex(Profit Hunter)

Jan 15, 2020

These stocks can move twice as fast as the Sensex - to take advantage of their money multiplying power get in now as the rally is still just taking shape.. read more to not miss out.

What the Infosys Results Tell Us About the Next Infosys(The 5 Minute Wrapup)

Jan 15, 2020

If you're interested in the next Infosys, I'll tell you where to look.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get our special report, Secret to Increasing Your Trading Profits Today Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Jan 22, 2020 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS - UNICHEM LAB COMPARISON

COMPARE NOVARTIS WITH

MARKET STATS